Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 76
- Registration Number
- NCT00319969
- Locations
- 🇺🇸
New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸Johns Hopkins Hospital - The Bunting Blaustein Cancer Research Building, Baltimore, Maryland, United States
🇺🇸Hematology/Oncology Consultants, St. Louis, Missouri, United States
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00317772
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 77
- Registration Number
- NCT00316173
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT00316186
- Locations
- 🇵🇱
GSK Investigational Site, Poznan, Poland
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
- Conditions
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00315861
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- John P. Fruehauf
- Target Recruit Count
- 40
- Registration Number
- NCT00314678
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Oxaliplatin and Topotecan in Advance Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-11-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00313612
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Jeffrey N. Bruce
- Target Recruit Count
- 18
- Registration Number
- NCT00308165
- Locations
- 🇺🇸
Columbia University Medical Center Neurological Institute, New York, New York, United States
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 61
- Registration Number
- NCT00305942
- Locations
- 🇺🇸
Family Cancer Center, Collierville, Tennessee, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸Montana Cancer Institute Foundation, Missoula, Montana, United States
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
- Conditions
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT00295243
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.